These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36278349)

  • 1. Synaptic Proteins as Fluid Biomarkers in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Roveta F; Cermelli A; Boschi S; Ferrandes F; Grassini A; Marcinnò A; Spina M; Rubino E; Borsello T; Vercelli A; Rainero I
    J Alzheimers Dis; 2022; 90(4):1381-1393. PubMed ID: 36278349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer's disease.
    Kivisäkk P; Carlyle BC; Sweeney T; Quinn JP; Ramirez CE; Trombetta BA; Mendes M; Brock M; Rubel C; Czerkowicz J; Graham D; Arnold SE
    Alzheimers Res Ther; 2022 Apr; 14(1):58. PubMed ID: 35461266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study.
    Vrillon A; Mouton-Liger F; Martinet M; Cognat E; Hourregue C; Dumurgier J; Bouaziz-Amar E; Brinkmalm A; Blennow K; Zetterberg H; Hugon J; Paquet C
    Alzheimers Res Ther; 2022 May; 14(1):71. PubMed ID: 35606871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer's disease continuum.
    Goossens J; Cervantes González A; Dewit N; Lidón L; Fortea J; Alcolea D; Lleó A; Belbin O; Vanmechelen E
    Alzheimers Res Ther; 2023 Oct; 15(1):186. PubMed ID: 37898760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
    Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P
    Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases.
    Nilsson J; Pichet Binette A; Palmqvist S; Brum WS; Janelidze S; Ashton NJ; Spotorno N; Stomrud E; Gobom J; Zetterberg H; Brinkmalm A; Blennow K; Hansson O
    Brain; 2024 Jul; 147(7):2414-2427. PubMed ID: 38325331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia.
    Clarke MTM; Brinkmalm A; Foiani MS; Woollacott IOC; Heller C; Heslegrave A; Keshavan A; Fox NC; Schott JM; Warren JD; Blennow K; Zetterberg H; Rohrer JD
    Alzheimers Res Ther; 2019 Dec; 11(1):105. PubMed ID: 31847891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synaptic Molecular and Neurophysiological Markers Are Independent Predictors of Progression in Alzheimer's Disease.
    Smailovic U; Kåreholt I; Koenig T; Ashton NJ; Winblad B; Höglund K; Nilsson P; Zetterberg H; Blennow K; Jelic V
    J Alzheimers Dis; 2021; 83(1):355-366. PubMed ID: 34334389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease.
    Kvartsberg H; Lashley T; Murray CE; Brinkmalm G; Cullen NC; Höglund K; Zetterberg H; Blennow K; Portelius E
    Acta Neuropathol; 2019 Jan; 137(1):89-102. PubMed ID: 30244311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer's disease and frontotemporal dementia.
    Das S; Goossens J; Jacobs D; Dewit N; Pijnenburg YAL; In 't Veld SGJG; Teunissen CE; Vanmechelen E
    Alzheimers Res Ther; 2023 Mar; 15(1):62. PubMed ID: 36964594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
    Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal Fluid Concentration of Neurogranin in Hip Fracture Patients with Delirium.
    Halaas NB; Zetterberg H; Idland AV; Knapskog AB; Watne LO; Blennow K
    J Alzheimers Dis; 2021; 81(2):667-677. PubMed ID: 33814433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurogranin and VILIP-1 as Molecular Indicators of Neurodegeneration in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Dulewicz M; Kulczyńska-Przybik A; Mroczko B
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33172069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The synaptic marker neurogranin as a disease state biomarker in Alzheimer's disease: a systematic review and meta-analysis.
    Wang Z; Yang J; Zhu W; Tang Y; Jia J
    Int J Neurosci; 2022 Dec; 132(12):1245-1253. PubMed ID: 33527855
    [No Abstract]   [Full Text] [Related]  

  • 15. Cerebrospinal fluid catecholamines in Alzheimer's disease patients with and without biological disease.
    Henjum K; Watne LO; Godang K; Halaas NB; Eldholm RS; Blennow K; Zetterberg H; Saltvedt I; Bollerslev J; Knapskog AB
    Transl Psychiatry; 2022 Apr; 12(1):151. PubMed ID: 35397615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis on CSF neurogranin levels for the diagnosis of Alzheimer's disease and mild cognitive impairment.
    Mavroudis IA; Petridis F; Chatzikonstantinou S; Kazis D
    Aging Clin Exp Res; 2020 Sep; 32(9):1639-1646. PubMed ID: 31463927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.
    De Vos A; Struyfs H; Jacobs D; Fransen E; Klewansky T; De Roeck E; Robberecht C; Van Broeckhoven C; Duyckaerts C; Engelborghs S; Vanmechelen E
    J Alzheimers Dis; 2016 Jul; 53(4):1523-38. PubMed ID: 27392859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer's Disease: A Pilot Study.
    Thordardottir S; Almkvist O; Johansson C; Zetterberg H; Blennow K; Graff C
    J Alzheimers Dis; 2020; 76(3):941-953. PubMed ID: 32568193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid biomarkers in the Longitudinal Early-onset Alzheimer's Disease Study.
    Dage JL; Eloyan A; Thangarajah M; Hammers DB; Fagan AM; Gray JD; Schindler SE; Snoddy C; Nudelman KNH; Faber KM; Foroud T; Aisen P; Griffin P; Grinberg LT; Iaccarino L; Kirby K; Kramer J; Koeppe R; Kukull WA; La Joie R; Mundada NS; Murray ME; Rumbaugh M; Soleimani-Meigooni DN; Toga AW; Touroutoglou A; Vemuri P; Atri A; Beckett LA; Day GS; Graff-Radford NR; Duara R; Honig LS; Jones DT; Masdeu JC; Mendez MF; Musiek E; Onyike CU; Riddle M; Rogalski E; Salloway S; Sha SJ; Turner RS; Wingo TS; Wolk DA; Womack KB; Carrillo MC; Dickerson BC; Rabinovici GD; Apostolova LG;
    Alzheimers Dement; 2023 Nov; 19 Suppl 9(Suppl 9):S115-S125. PubMed ID: 37491668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease.
    De Vos A; Jacobs D; Struyfs H; Fransen E; Andersson K; Portelius E; Andreasson U; De Surgeloose D; Hernalsteen D; Sleegers K; Robberecht C; Van Broeckhoven C; Zetterberg H; Blennow K; Engelborghs S; Vanmechelen E
    Alzheimers Dement; 2015 Dec; 11(12):1461-1469. PubMed ID: 26092348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.